{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T05:04:08Z","timestamp":1795151048487,"version":"4.10.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018854","name":"Sirtex","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018854","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Selective internal radiation therapy (SIRT) with yttrium-90 (<jats:sup>90<\/jats:sup>Y) resin microspheres is an established locoregional treatment option for unresectable hepatocellular carcinoma (HCC), which delivers a lethal dose of radiation to hepatic tumors, while sparing surrounding healthy tissue. DOORwaY90 is a prospective, multicenter, open-label, single arm study, designed to evaluate the safety and effectiveness of <jats:sup>90<\/jats:sup>Y resin microspheres as first-line treatment in patients with unresectable\/unablatable HCC. It is unique in that it is the first study with resin microspheres to utilize a personalized <jats:sup>90<\/jats:sup>Y dosimetry approach, and independent review for treatment planning and response assessment.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Eligibility criteria include unresectable\/unablatable HCC, Barcelona Clinic Liver Cancer stage A, B1, B2, or C with a maximal single tumor diameter of\u2009\u2264\u20098\u00a0cm, and a sum of maximal tumor diameters of\u2009\u2264\u200912\u00a0cm, and at least one tumor\u2009\u2265\u20092\u00a0cm (long axis) per localized, modified Response Evaluation Criteria in Solid Tumors. Partition model dosimetry is used to determine the optimal dose; the target mean dose to tumor is\u2009\u2265\u2009150\u00a0Gy. Patients are assessed at baseline and at regular intervals up until 12\u00a0months of treatment for response rates, safety, and quality of life (QoL). Post-treatment dosimetry is used to assess dose delivered to tumor and consider if retreatment is necessary. The co-primary endpoints are best objective response rate and duration of response. Secondary endpoints include grade\u2009\u2265\u20093 toxicity, QoL, and incidence of liver resection and transplantation post SIRT. Target recruitment is 100 patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The results of this trial should provide further information on the potential use of SIRT with <jats:sup>90<\/jats:sup>Y resin microspheres as first-line therapy for unresectable HCC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>\n                           <jats:italic>Trial registration<\/jats:italic>\n                        <\/jats:title>\n                <jats:p>Clinicaltrials.gov; NCT04736121; date of 1st registration, January 27, 2021, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04736121\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04736121<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-022-02204-1","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T04:32:10Z","timestamp":1648528330000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["A prospective, multicenter, open-label, single-arm clinical trial design to evaluate the safety and efficacy of 90Y resin microspheres for the treatment of unresectable HCC: the DOORwaY90 (Duration Of Objective Response with arterial Ytrrium-90) study"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0416-4566","authenticated-orcid":false,"given":"Armeen","family":"Mahvash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Chartier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Turco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Griffith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4643-7745","authenticated-orcid":false,"given":"S. Cheenu","family":"Kappadath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,28]]},"reference":[{"key":"2204_CR1","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.3390\/ijms20061465","volume":"20","author":"I Lurje","year":"2019","unstructured":"Lurje I, Czigany Z, Bednarsch J, Roderburg C, Isfort P, Neumann UP, et al. Treatment strategies for hepatocellular carcinoma\u2014a multidisciplinary approach. Int J Mol Sci. 2019;20:1465.","journal-title":"Int J Mol Sci."},{"key":"2204_CR2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"2204_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","volume":"10","author":"V Mazzaferro","year":"2009","unstructured":"Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35\u201343.","journal-title":"Lancet Oncol"},{"key":"2204_CR4","doi-asserted-by":"publisher","first-page":"5282","DOI":"10.3748\/wjg.v23.i29.5282","volume":"23","author":"D Dimitroulis","year":"2017","unstructured":"Dimitroulis D, Damaskos C, Valsami S, Davakis S, Garmpis N, Spartalis E, et al. From diagnosis to treatment of hepatocellular carcinoma: an epidemic problem for both developed and developing world. World J Gastroenterol. 2017;23:5282\u201394.","journal-title":"World J Gastroenterol"},{"key":"2204_CR5","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jhep.2005.10.002","volume":"44","author":"HB El-Serag","year":"2006","unstructured":"El-Serag HB, Siegel AB, Davila JA, Shaib YH, Cayton-Woody M, McBride R, et al. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol. 2006;44:158\u201366.","journal-title":"J Hepatol"},{"key":"2204_CR6","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.ijrobp.2004.09.004","volume":"60","author":"AS Kennedy","year":"2004","unstructured":"Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys. 2004;60:1552\u201363.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2204_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s00534-002-0720-z","volume":"10","author":"S Arii","year":"2003","unstructured":"Arii S, Teramoto K, Kawamura T. Current progress in the understanding of and therapeutic strategies for ischemia and reperfusion injury of the liver. J Hepatobiliary Pancreat Surg. 2003;10:189\u201394.","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"2204_CR8","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3390\/cancers12020294","volume":"12","author":"E Birgin","year":"2020","unstructured":"Birgin E, Rasbach E, Seyfried S, Rathmann N, Diehl SJ, Schoenberg SO, et al. Contralateral liver hypertrophy and oncological outcome following radioembolization with (90)Y-microspheres: a systematic review. Cancers (Basel). 2020;12:294.","journal-title":"Cancers (Basel)."},{"key":"2204_CR9","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.surg.2017.10.014","volume":"163","author":"JY Teo","year":"2018","unstructured":"Teo JY, Allen JC, Ng DCE, Abdul Latiff JB, Choo SP, Tai DW, et al. Prospective study to determine early hypertrophy of the contra-lateral liver lobe after unilobar, Yttrium-90, selective internal radiation therapy in patients with hepatocellular carcinoma. Surgery. 2018;163:1008\u201313.","journal-title":"Surgery"},{"key":"2204_CR10","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1002\/hep.26947","volume":"59","author":"B Garlipp","year":"2014","unstructured":"Garlipp B, de Baere T, Damm R, Irmscher R, van Buskirk M, Stubs P, et al. Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization. Hepatology. 2014;59:1864\u201373.","journal-title":"Hepatology"},{"key":"2204_CR11","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","volume":"18","author":"V Vilgrain","year":"2017","unstructured":"Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18:1624\u201336.","journal-title":"Lancet Oncol"},{"key":"2204_CR12","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","volume":"36","author":"PKH Chow","year":"2018","unstructured":"Chow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, Ong J, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36:1913\u201321.","journal-title":"J Clin Oncol"},{"key":"2204_CR13","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jhep.2019.08.006","volume":"71","author":"J Ricke","year":"2019","unstructured":"Ricke J, Klumpen HJ, Amthauer H, Bargellini I, Bartenstein P, de Toni EN, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol. 2019;71:1164\u201374.","journal-title":"J Hepatol"},{"key":"2204_CR14","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1007\/s00259-020-05163-5","volume":"48","author":"H Levillain","year":"2021","unstructured":"Levillain H, Bagni O, Deroose CM, Dieudonne A, Gnesin S, Grosser OS, et al. International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur J Nucl Med Mol Imaging. 2021;48:1570\u201384.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2204_CR15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1053\/jlts.2002.31654","volume":"8","author":"JN Vauthey","year":"2002","unstructured":"Vauthey JN, Abdalla EK, Doherty DA, Gertsch P, Fenstermacher MJ, Loyer EM, et al. Body surface area and body weight predict total liver volume in Western adults. Liver Transpl. 2002;8:233\u201340.","journal-title":"Liver Transpl"},{"key":"2204_CR16","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00270-007-9064-z","volume":"30","author":"RJ Lewandowski","year":"2007","unstructured":"Lewandowski RJ, Sato KT, Atassi B, Ryu RK, Nemcek AA Jr, Kulik L, et al. Radioembolization with 90Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol. 2007;30:571\u201392.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2204_CR17","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/BF01084369","volume":"23","author":"S Ho","year":"1996","unstructured":"Ho S, Lau WY, Leung TW, Chan M, Ngar YK, Johnson PJ, et al. Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med. 1996;23:947\u201352.","journal-title":"Eur J Nucl Med"},{"key":"2204_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ijrobp.2019.02.032","volume":"105","author":"CE Hsieh","year":"2019","unstructured":"Hsieh CE, Venkatesulu BP, Lee CH, Hung SP, Wong PF, Aithala SP, et al. Predictors of radiation-induced liver disease in Eastern and Western patients with hepatocellular carcinoma undergoing proton beam therapy. Int J Radiat Oncol Biol Phys. 2019;105:73\u201386.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2204_CR19","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1148\/radiol.2020191606","volume":"296","author":"A-L Hermann","year":"2020","unstructured":"Hermann A-L, Dieudonne A, Ronot M, Sanchez M, Pereira H, Chatellier G, et al. Relationship of tumor radiation-absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with yttrium-90 in the SARAH study. Radiology. 2020;296:673\u201384.","journal-title":"Radiology"},{"key":"2204_CR20","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.2967\/jnumed.110.075861","volume":"51","author":"L Strigari","year":"2010","unstructured":"Strigari L, Sciuto R, Rea S, Carpanese L, Pizzi G, Soriani A, et al. Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations. J Nucl Med. 2010;51:1377\u201385.","journal-title":"J Nucl Med"},{"key":"2204_CR21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52\u201360.","journal-title":"Semin Liver Dis"},{"key":"2204_CR22","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1016\/j.jvir.2018.07.006","volume":"29","author":"C Allimant","year":"2018","unstructured":"Allimant C, Kafrouni M, Delicque J, Ilonca D, Cassinotto C, Assenat E, et al. Tumor targeting and three-dimensional voxel-based dosimetry to predict tumor response, toxicity, and survival after yttrium-90 resin microsphere radioembolization in hepatocellular carcinoma. J Vasc Interv Radiol. 2018;29:1662-70 e4.","journal-title":"J Vasc Interv Radiol."},{"key":"2204_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","volume":"6","author":"E Garin","year":"2021","unstructured":"Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6:17\u201329.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2204_CR24","doi-asserted-by":"crossref","unstructured":"Willowson KP, Tapner M, Team QI, Bailey DL. A multicentre comparison of quantitative (90)Y PET\/CT for dosimetric purposes after radioembolization with resin microspheres : the QUEST Phantom Study. Eur J Nucl Med Mol Imaging. 2015;42:1202\u201322.","DOI":"10.1007\/s00259-015-3059-9"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02204-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-022-02204-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02204-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T04:44:23Z","timestamp":1648529063000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-022-02204-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,28]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2204"],"URL":"https:\/\/doi.org\/10.1186\/s12876-022-02204-1","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,28]]},"assertion":[{"value":"10 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All relevant institutional and local ethics committee approvals were gained before commencing the study. A full list of institutional review board (IRB) approvals is supplied in the Additional file . Written informed consent is obtained from all participants (or their legally authorized representatives) prior to participation in this study. Consent will be obtained by the investigator. All data used in the analysis and reporting of this study will be without identifiable references to a participant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AM has acted as a consultant and received research support from Sirtex, BTG\/Boston Scientific, Siemens Healthineers and ABK Biomedical. SC, MT, PH, and SG are employees of Sirtex Medical. SB is an employee of Bright Research Partners and has acted as a consultant to Sirtex. SCK has acted as a consultant to Sirtex and ABK Medical, and has received research support from Boston Scientific, ABK Biomedical and GE Healthcare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"151"}}